坎格罗尔在急性和高风险PCI环境中的作用
Uwe Zeymer1,2, Tobias Geisler3, Dirk Westermann2
1Institut für Herzinfarktforschung Ludwigshafen, Bremserstrasse 79, Ludwigshafen 67063, Germany.
概括
静脉注射的康格罗尔为高风险皮肤冠状动脉干预 (PCI) 患者提供了可靠的抗血小板策略,克服了急性冠状动脉综合征中口服P2Y12抑制剂的局限性. 这种方法确保在关键过程中有效地抑制血小板.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 干预心脏病学 干预心脏病学
背景情况:
- 与阿司匹林 (ASA) 和口服P2Y12抑制剂的双重抗血小板疗法 (DAPT) 是预防经皮肤冠状动脉干预 (PCI) 后血栓事件的标准.
- 口服P2Y12抑制剂在急性,高风险的PCI场景中具有显著的限制,包括带有心脏性休克 (CS) 或心脏骤停 (CA) 的ST升高心肌梗塞 (STEMI).
- 诸如吐,生理变化,通风和低温等因素会影响口服药物吸收,降低抗血小板功效,增加这些关键患者的缺血风险.
研究的目的:
- 审查静脉注射康格罗尔作为一种替代性抗血小板策略在急性和高风险PCI环境中的作用.
- 要突出康格罗尔的药理动力学和药理动力学特性,使其适合于这些具有挑战性的临床场景.
- 总结关于康格雷罗的采用现实世界的证据,并为其使用和向口服药物过渡提供实际指导.
主要方法:
- 复习的药理动力学和药理动力学属性.
- 综合现实世界研究中的证据,以当代实践中使用草.
- 开发一本关于 cangrelor 管理和PCI 后过渡战略的实用指南.
主要成果:
- 康格洛尔的药理动力学和药理动力学概况提供了快速发病和抵消,确保可预测的血小板抑制.
- 现实世界的数据表明,康格罗尔在急性和高风险的PCI中有效使用,解决了口服药物的局限性.
- 提供了使用草和无过渡到口服P2Y12抑制剂的指导方针.
结论:
- 在急性和高风险的PCI中,静脉内输入的康格罗尔为口服P2Y12抑制剂提供了有价值的替代品,特别是在CS或CA的STEMI患者中.
- 康格洛尔确保了足够的周围过程性血小板抑制,在口服吸收受到损害时减轻缺血风险.
- 实践指南有助于有效地实施康格罗尔疗法,并随后转向口服P2Y12抑制剂.
更多相关视频
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.6K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
9.0K
相关概念视频
01:28Acute Coronary Syndrome IV: Interprofessional Care
220
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220
01:27Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
01:26Angina IV: Management
241
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
241
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
01:20Angina V: Nursing Management
296
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
296
01:30Acute Coronary Syndrome I: Introduction
835
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
835